Article from the National Cancer Institute curated by Editor in Chief George Lundberg, MD, who notes:
In 2019, the U.S. Food and Drug Administration (FDA) approved pembrolizumab for certain advanced esophageal cancers, depending on testing results. The National Cancer Institute explains here.
Go to full article published by the National Cancer Institute.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.